Market Overview

ImmunoGen's Turnaround Is 'In Full-Swing' Following ASCO Presentations

ImmunoGen's Turnaround Is 'In Full-Swing' Following ASCO Presentations

Shares of ImmunoGen, Inc. (NASDAQ: IMGN) were trading higher by more than 6 percent on Thursday, partly due to an upgrade from analysts at RBC Capital Markets.

RBC's Matthew Eckler, Ph.D., upgrades ImmunoGen's stock from Sector Perform to Outperform with a price target boosted from $5 to $12 due to an increased conviction in a Phase 3 trial exploring mirvetuximab coupled with management's ongoing turnaround effort.

More Constructive On Mirvetuximab

ImmunoGen's presentation at ASCO 2017 included an update on mirvetuximab single-agent results and pooled data from three separate Phase 1 cohorts, the analyst continued. Perhaps most notably, 36 platinum-resistant patients met the Phase III FORWARD I enrollment criteria.

"Among these patients the ORR was 47%, with a median PFS of 6.7 months," Eckler explained. "This compares favorably to results with paclitaxel, PLD, or topotecan, as well as from Avastin (bevacizumab) in the AURELIA trial (27% ORR; 6.7 month mPFS), which enrolled patients who received fewer prior therapies."


Now that mirvetuximab has demonstrated comparable efficacy in three separate Phase 1 cohorts as supportive of the company's move to advance the agent into Phase 3 trials, the analyst continued. This also provides "assurances around its probability of success."

Turnaround Initiatives

ImmunoGen has been busy in monetizing non-core assets and this provides "concrete evidence" of management's commitment to its turnaround efforts, Eckler also stated. The company's ultimate objective is to focus squarely on advancing mirvetuximab, which is a bullish sign for the stock.

"So while acknowledging that we may be somewhat late to the party, we think there remains significant room for upside at current levels," the analyst wrote.

At time of publication, shares of ImmunoGen were up 9.25 percent at $7.97.

Related Links:

Benzinga's Top Upgrades, Downgrades For July 6, 2017

Kite Pharma A Top Pick Ahead Of Axi-Cel Launch

Posted-In: Analyst Color Biotech Long Ideas News Upgrades Price Target Analyst Ratings Movers Best of Benzinga


Related Articles (IMGN)

View Comments and Join the Discussion!

Do Valeant Fundamentals Justify The Decrease In Bearish Sentiment?

Boon Investments Brings Robo- Advisory Services to the World